Quest Diagnostics Incorporated (DGX)
| Market Cap | 15.51B |
| Revenue (ttm) | 9.44B |
| Net Income (ttm) | 1.43B |
| Shares Out | 134.77M |
| EPS (ttm) | 10.47 |
| PE Ratio | 11.27 |
| Forward PE | 10.46 |
| Dividend | $2.24 |
| Dividend Yield | 1.90% |
| Trading Day | March 5 |
| Last Price | $117.96 |
| Previous Close | $117.28 |
| Change ($) | 0.68 |
| Change (%) | 0.58% |
| Day's Open | 117.88 |
| Day's Range | 115.75 - 118.32 |
| Day's Volume | 1,533,548 |
| 52-Week Range | 71.76 - 134.71 |
Davis Select Advisors recently released its fourth-quarter 2020 portfolio update. Among the changes made during the quarter, the firm disclosed a new position in Viatris Inc. (NASDAQ:VTRS), a ...
SECAUCUS, N.J., Feb. 24, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today introduced a new COVID-19 testing service th...
SECAUCUS, N.J., Feb. 23, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced changes in the leadership o...
MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced an agreement with Quest Diagnostics (NYSE:...
NEW YORK and SECAUCUS, N.J., Feb. 16, 2021 /PRNewswire/ -- EmblemHealth, one of the nation's largest non-profit health insurers, and Quest Diagnostics (NYSE: DGX), the world's leading provider...
SECAUCUS, N.J., Feb. 9, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, will host a virtual Investor Day for institutional ...
Quest Diagnostics CEO: We see very limited re-infection of Covid-19
Steve Rusckowski, Quest Diagnostics CEO, joins 'Closing Bell' to discuss coronavirus testing, covid variants, and his outlook on the pandemic as coronavirus cases decrease in the U.S.
Quest Diagnostics' (DGX) first-half 2021 outlook looks impressive thanks to strong revenue growth expectations.
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.67% and 2.25%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
SECAUCUS, N.J., Feb. 4, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for ...
SECAUCUS, N.J., Feb. 4, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the Company's Board of...
Top growth stocks to watch include Quest Diagnostics, which is breaking out to new highs ahead of its Q4 earnings due out this week. The post Quest Diagnostics Stock Near Buy Point As Covid-19...
SECAUCUS, N.J., Feb. 1, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been selected as one of...
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Within non-COVID base business, Quest Diagnostics (DGX) is expected to have secured higher returns in Q4 from the acquisitions of MACL, Memorial Hermann Outreach and Blueprint Genetics.
Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.
3 Outpatient Home Health Stocks Set to Ride the Industry's Upturn
Quest Diagnostics (DGX) notes strong signs of the healthcare system returning to pre-pandemic levels with base testing volume gradually improving.
SECAUCUS, N.J., Jan. 18, 2021 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has entered into an agreem...
SECAUCUS, N.J., Jan. 13, 2021 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth ...
The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.
In the latest trading session, Quest Diagnostics (DGX) closed at $123.63, marking a +0.54% move from the previous day.
Quest Diagnostics (DGX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics (DGX) closed at $121.74 in the latest trading session, marking a +0.51% move from the prior day.
Quest Diagnostics has effectively captured 24% of a $28Bn market, while earning the loyalty of 11Mn customers digitally by providing low cost, high quality services at one-eighth the cost. The...
Is (DGX) Outperforming Other Medical Stocks This Year?
Quest Diagnostics Incorporated (DGX) has been struggling lately, but the selling pressure may be coming to an end soon.
In the latest trading session, Quest Diagnostics (DGX) closed at $118.40, marking a -0.08% move from the previous day.
Quest Diagnostics (DGX) collaborates with Hackensack Meridian Health to manage laboratory operation and provide high-quality healthcare network.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...
SECAUCUS, N.J. and NUTLEY, N.J., Dec. 22, 2020 /PRNewswire/ -- Hackensack Meridian Health (HMH), the largest, most comprehensive and truly integrated health care network in New Jersey, and Que...
In the latest trading session, Quest Diagnostics (DGX) closed at $120.85, marking a +0.41% move from the previous day.
SECAUCUS, N.J., Dec. 17, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and The Commons Project, a non-profit public trust...
Shares of Quest Diagnostics Inc. rose 0.7% in premarket trading Wednesday, after the clinical lab testing company raised its full-year profit, revenue and cash flow outlook, as COVID-19 molecu...
SECAUCUS, N.J., Dec. 16, 2020 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today raised its financial outlook fo...
Quest Diagnostics (DGX) closed the most recent trading day at $123.16, moving +0.9% from the previous trading session.
When screening the market in search of value opportunities, one method is to look for stocks whose trailing 12-month price-to-free-cash-flow ratios are low compared to that of the S&P 500 inde...
SECAUCUS, N.J., Dec. 9, 2020 /PRNewswire/ -- A new Quest Diagnostics Health Trends™ study finds that three in four Americans who believed they needed a COVID-19 test (74%) chose not to get one...
Our indicative theme of Covid-19 Testing Stocks- which includes the stocks of companies that produce or carry out tests for the highly infectious virus - is up by about 51% year-to-date, on an...
Let's see if Quest Diagnostics (DGX) stock is a good choice for value-oriented investors right now from multiple angles.
Quest Diagnostics (DGX) is moving ahead in terms of its growth strategy, which consists of five elements.
SECAUCUS, N.J., Nov. 24, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has achieved Gold status i...
Quest Diagnostics has seen strong revenue and earnings bumps due to COVID-19 testing. While the pandemic won't last forever, I see management setting up the company for long-term success.
Quest Diagnostics saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 93 the day before. The post Quest Diagnostics Stock Rating Improves Amid Surging Covid Testing Rates appea...
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
SECAUCUS, N.J., Nov. 18, 2020 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declar...
Cramer on four coronavirus testing stocks worth owning
"I bet the testing stocks have a lot more room to run," the "Mad Money" host said.
Our indicative theme of Covid-19 Testing Stocks, which includes medical device and diagnostic companies that are involved in Covid-19 testing – is up by about 66% year-to-date, significantly o...
About DGX
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hos... [Read more...]
| Industry Diagnostics & Research | IPO Date Dec 17, 1996 |
| CEO Stephen Rusckowski | Employees 40,000 |
| Stock Exchange NYSE | Ticker Symbol DGX |
Financial Performance
In 2020, DGX's revenue was $9.44 billion, an increase of 22.15% compared to the previous year's $7.73 billion. Earnings were $1.43 billion, an increase of 66.78%.
Analyst Forecasts
According to 18 analysts, the average rating for DGX stock is "Buy." The 12-month stock price forecast is 140.40, which is an increase of 19.02% from the latest price.